However, NSUN7 promoter CpG island was methylated among different cancer types (Dataset S1D, Fig. 1A), being the three most often targeted sites in melanoma (35 of 47, 74.5%), liver cancer (11 of 18, 61.1%) and hematological malignancies (77 of 137, 56.2%). Here, NSUN7 is linked to hematologic disorder.